Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years

Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with β-thalassemia major

(2014) Maddalena Casale et al.   AMERICAN JOURNAL OF HEMATOLOGY

Serum ferritin levels and endocrinopathy in medically treated patients with β thalassemia major

(2012) Khawla M. Belhoul et al.   ANNALS OF HEMATOLOGY

Differential effects of the type of iron chelator on the absolute number of hematopoietic peripheral progenitors in patients with  -thalassemia major

(2012) G. L. Forni et al.   HAEMATOLOGICA

Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with  -thalassemia major

(2012) D. J. Pennell et al.   HAEMATOLOGICA

Pancreatic iron and glucose dysregulation in thalassemia major

(2011) Leila J. Noetzli et al.   AMERICAN JOURNAL OF HEMATOLOGY

Pituitary iron and volume predict hypogonadism in transfusional iron overload

(2011) Leila J. Noetzli et al.   AMERICAN JOURNAL OF HEMATOLOGY

Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up

(2011) M. D. Cappellini et al.   BLOOD

Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications

(2011) Kallistheni Farmaki et al.   BLOOD CELLS MOLECULES AND DISEASES

Improvement in Liver Pathology of Patients With β-Thalassemia Treated With Deferasirox for at Least 3 Years

(2011) Yves Deugnier et al.   GASTROENTEROLOGY

Bone disease and skeletal complications in patients with β thalassemia major

(2010) Rachid Haidar et al.   BONE

Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major

(2009) Kallistheni Farmaki et al.   BRITISH JOURNAL OF HAEMATOLOGY